Search

Childhood cancer researcher named Researcher of the Year

A leading WA cancer researcher has been named the Cure Cancer 2026 Researcher of the Year for his groundbreaking work in paediatric leukaemia.

Beyond the horizon: improving cancer outcomes for Indigenous children

Dr Jessica Buck, a researcher at The Kids Research Institute Australia Cancer Centre and a Kamilaroi woman, is on a mission to address the unique challenges faced by Aboriginal and Torres Strait Islander children with cancer.

Childhood cancers not on the rise in SA and NT, but disparity remains for Indigenous children in the NT

Despite national and global reports of rising incidences of cancer affecting children and young people, a new analysis has found rates of childhood cancer have remained unchanged over the last 30 years in South Australia and the Northern Territory.

Precision medicine offering new hope for kids with aggressive cancers

A world-first study involving more than 100 cancer researchers and clinicians across Australia – including from The Kids Research Institute Australia and Perth Children’s Hospital – has shown that precision medicine can significantly improve outcomes for children with high-risk cancer.

WA-based cancer pharmaceutical start-up secures CUREator funding

Researchers dedicated to developing the first cancer immunotherapy tablet have been boosted by a $374,000 CUREator top-up funding grant.

World-first research to transform outcomes for First Nations children with cancer

A first of its kind research program at The Kids Research Institute Australia aims to develop new strategies to better treat First Nations children with cancer.

WA Kids Cancer Centre researchers appointed to Brain Cancer Expert Advisory Panel

Dr Jessica Buck and Associate Professor Raelene Endersby have been appointed to the prestigious Australian Brain Cancer Mission Expert Advisory Panel.

Silencing of TESTIN by dense biallelic promoter methylation

Aberrant promoter DNA methylation has been reported in childhood acute lymphoblastic leukaemia and has the potential to contribute to its onset and outcome

Methotrexate-related central neurotoxicity: clinical characteristics, risk factors and genome-wide association study in children treated for acute lymphoblastic leukemia

Symptomatic methotrexate-related central neurotoxicity (MTX neurotoxicity) is a severe toxicity experienced during acute lymphoblastic leukemia (ALL) therapy with potential long-term neurologic complications. Risk factors and long-term outcomes require further study.

Acute Leukaemia of Ambiguous Lineage Presenting as a Focal Bone Lesion: a Case Report

Acute leukaemia is the most common childhood malignancy. Almost all cases are classified as acute lymphoblastic leukaemia or acute myeloid leukaemia. Acute leukaemia of ambiguous lineage (ALAL) is a rare form of acute leukaemia that cannot be classified by a single lineage. Like other acute leukaemias, ALAL typically presents with nonspecific symptoms such as fatigue, fever, or bleeding.